It has also been reported that the metallothionein-3 (MT3) level decreases in astrocytes in lesioned areas of degenerative diseases such as Parkinson's disease, amyothrophic lateral sclerosis, and progressive supranuclear palsy [5]. Here, MT3 is linked to progressive supranuclear palsy.